Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline

Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q3

STERIS' (STE) third-quarter fiscal 2021 results reflect strong performance by all three of its reporting segments despite the coronavirus-led economic crisis.

PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) fourth-quarter results benefit from strong segmental performance.

Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts

Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.

IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise

IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.

Why Abbott (ABT) Might be Well Poised for a Surge

Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes

Within pediatric nutrition, Abbott (ABT) registers U.S. sales growth led by increased market share of Similac infant formula brand.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q3

McKesson's (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.

Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts

Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.

The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, Abbott Laboratories, Starbucks and Target

The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, Abbott Laboratories, Starbucks and Target

Sheraz Mian headshot

Top Research Reports for Netflix, Bristol-Myers & Abbott

Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Bristol-Myers Squibb (BMY), and Abbott Laboratories (ABT).

Abbott (ABT) Moves to Buy: Rationale Behind the Upgrade

Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Urmimala Biswas headshot

3 MedTech Stocks Likely to Top Estimates This Earnings Season

Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.

Durable Goods Orders For December Rose Lower-than-Expected

Durable Goods Orders For December Rose Lower-than-Expected

Abbott (ABT) Q4 Earnings Top, Diagnostic Test Sales Solid

Within Diabetes Care, Abbott (ABT) reports strong sales banking on growing demand for sensor-based continuous glucose monitoring system, FreeStyle Libre.

Mark Vickery headshot

Pre-Markets Sell Off Ahead of Big Q4 Earnings

It seems a new round of profit-taking is manifesting itself ahead of what will be the single-most consequential day of earnings season so far.

Abbott (ABT) Beats Q4 Earnings and Revenue Estimates

Abbott (ABT) delivered earnings and revenue surprises of 6.62% and 8.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

5 Incredible Perfect Earnings Charts

It's not easy to beat every quarter on earnings for five years, including during a global pandemic. These companies have done it.

QIAGEN (QGEN) Announces COVID-19 Test Updates as Cases Rise

QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.

Boston Scientific's (BSX) DBS System Gets FDA's Clearance

The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.

Demand for COVID-19 Tests to Drive Abbott (ABT) Q4 Earnings

Within EPD, Abbott (ABT) is expected to have witnessed visible signs of rebound through Q4.

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic

Urmimala Biswas headshot

Federal, Private Tie-Ups Boost COVID-19 Testing Volume

The Department of Health and Human Services (HHS) promises over $22 billion of funding.

What's in Store for UnitedHealth (UNH) This Earnings Season?

UnitedHealth's (UNH) earnings results are likely to reflect solid contribution from its segments, namely Healthcare and Optum, partly offset by higher claim costs.

What's in Store for Intuitive Surgical's (ISRG) Q4 Earnings?

Intuitive Surgical's (ISRG) fourth-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.